0001193125-26-211939
SEC filingOtsuka collaboration drove first significant revenue of $3.0M via clinical trial cost-sharing, offsetting R&D escalation from wet AMD trials that widened operating losses to $73.6M and accelerated cash burn in this clinical-stage biotech.
Revenue increased to $3.0 million in Q1 FY2026 from $14 thousand in the prior year, primarily due to clinical trial cost sharing and reimbursement amounts from Otsuka. This marks the company's first meaningful topline progress, reflecting activation of collaboration terms that offset some clinical development costs.
Net income followed suit at -$68.8 million versus -$48.0 million last year, yielding diluted EPS of -$1.01 compared to -$0.86. This reflects the operating loss expansion without sufficient revenue scale to achieve breakeven, underscoring the pre-commercial stage risks.
Looking forward, transition to profitability hinges on successful development, approval, and commercialization of product candidates like 4D-150, alongside collaboration partners achieving revenue levels to cover the cost structure. The company expects continued losses, with prior and anticipated deficits impacting working capital. This quarter's revenue milestone validates the Otsuka partnership's cost-sharing benefits, but escalating clinical spend signals heightened execution risk in wet AMD Phase 3 advancement.